Method for Inducing a Trif-Bias
AssigneeGlaxosmithkline Biologicals SA
InventorsWilliam S. Bowen, Jay T. Evans, Melinda M. Hutton, David A. Johnson, Laurie A. Minns
Life of this patent
Estimating the term…
Abstract
The use of a selected aminoalkyl glusoaminide 4-phosphate (AGP) CRX-547 to induce a TRIF biased response in a human system, which results in reduced levels of MyD88-dependent cytokines relative to the MyD88-dependent cytokines induced by its diastereomer AGP CRX-527.
Claims11
A method of reducing levels of MyD88-dependent cytokines induced when administering, to a human, a lipid A mimetic composition in the absence of CRX 547 comprising;
- administering in a human a lipid A mimetic composition comprising CRX547.
A method of manufacturing a human Lipid-A mimetic adjuvant composition capable of inducing lower levels of IL-12p70 and IL-23 comprising incorporating CRX547 into the lipid A adjuvant composition.
(canceled)
(canceled)
A method of improving a lipid A mimetic adjuvant composition's therapeutic index, wherein the lipid A mimetic adjuvant composition comprises a first lipid A mimetic that is not CRX547, the method comprising the step of incorporating CRX547 into the adjuvant composition.
10-19. (canceled)
Dependencies are inferred from the claim text.